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BACKGROUND
• Depression affects almost 10% of Americans over 18 years old.1
• Per the Centers for Disease and Control Prevention, the 2020
COVID-19 pandemic has led to an increase in adults struggling
with mental health.1
• There is currently a shortage of mental health prescribers, with
over half of all counties within the United States not having a single
psychiatrist.2
• Southern Oregon also has a shortage of mental health prescribers,
resulting in longer wait times for care.
• Evidence demonstrates that depression managed by pharmacists
in the primary care setting led to increased follow-up frequency,
increased medication adherence, improved PHQ-9 scores, and
patient satisfaction.3

PURPOSE
The purpose of this study is to quantify, characterize, assess, and
identify the management trends of clinical pharmacy specialists
(CPS) that are managing depression of patients at Providence
Medical Group (PMG).

METHODS
• A retrospective chart review was performed on patients who were
managed by a clinical pharmacist for depression from January
2019 through December 2020. This information was gathered via
the intervention tracking tool within the electronic medical record
(EMR). The endpoints below were gathered for evaluation of
management trends by the pharmacists.
• A presentation was provided to the PMG clinics in Southern
Oregon, reviewing the depression collaborative practice agreement
(CPA). Patients referred after this presentation were followed up to
four months and included in data analysis.
• In order to meet a power of 80%, the calculated sample size is 32.

Inclusion Criteria
• Patients whose depression was managed by clinical pharmacy
specialist from 1/1/2019 through 11/30/2020.
• Patients who were referred to clinical pharmacy specialist between
12/3/2020 and 2/28/2021.

Exclusion Criteria
• Any patient referred back to PCP for atypical presentation, goals of
therapy not met after multiple pharmacologic alternatives,
consideration of psychotherapy, or immediate risk of suicide.
• Pregnant patients

Primary Endpoints
•
•
•
•
•
•
•
•
•
•

Mean number and percent rate of follow-up visits
Number of agent changes
Number of dosage changes for a single agent
Reason for changing dose
Whether the intervention was guideline-directed
Whether adherence was addressed at any visit
Number of augmentation agents added
Frequency of PHQ-9 assessments performed
Mean change in PHQ-9
Referring member of care team

Secondary Endpoints
• The number of referrals obtained by clinical pharmacy services
from 12/3/2020 to 2/28/2021.

RESULTS

DISCUSSION

Table 1. Baseline Characteristics

Table 2. Primary Endpoints
Mean number of visits

Retrospective Retrospective
Data (n=25)
Data (n=7)
Mean Age, years
Female, %
Baseline PHQ-9 score

57
48%
16.5

59
100%
16.75

Comorbidities, n
Type 2 diabetes mellitus

15

1

Generalized anxiety
disorder

10

5

Chronic pain

4

1

Post-traumatic
stress
disorder

2

Cancer

2

Hypothyroidism

2

Alcohol misuse

1

1

Mean follow-up frequency

1

Parkinson’s Disease

1

Bulimia

4 weeks

Mean number agent switches per patient
over course of PharmD management
Median frequency of PHQ-9 Assessment

1.6
4.5 weeks

Mean change in PHQ-9 Score

-4.2

Total number of patients with augmentation
agents
Total number of dose increases

3
28

% of visits adherence was addressed

100%

• Non-pharmacologic measures were assessed at every patient
visit, including addressing presence of support system, meeting
with BHI, and exercise.
• Addressing adherence led to therapy changes based on patientspecific needs such as switching antidepressant therapy to a
longer-acting agent due to lack of adherence.
• There were
only three instances where regimens were
augmented with an additional agent. This potentially
indicates pharmacists were attempting to identify the best primary
medication before augmenting with an additional agent.
• At first visit, dose increase occurred for over 25% of the patients,
demonstrating potential benefit of dose increases prior to referrals.
• The mean decrease in PHQ-9 scores shows a clinically significant
improvement in depression severity for this subset of patients.

CONCLUSIONS
• Based on the total number of depression referrals received, the
depression CPA is currently underutilized.
• When a CPS is managing depression, there is consistent follow-up
to assess medication tolerance and response and more frequent
follow-up is available if needed.
• There was only one incidence where a medication was increased
to a dose that only had anecdotal evidence, demonstrating a
strong adherence to evidence-based practice by the clinical
pharmacists.
• These evidence-based and meaningful interventions resulted in
clinically significant improvements in depression severity.
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Figure 2: Referring Provider
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Figure 4: Reason for Drug Addition
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Figure 5: Reason for Dose Decrease

Contact Info
Primary Investigator: Adam Olesen, PharmD
Adam.Olesen@providence.org
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NEXT STEPS
• Streamline referral process to help identify patients who would
benefit from CPS depression management, especially those
already being managed by CPS for other disease states.
• Survey CPS team to identify potential barriers to depression
management and referral.
• Increase opportunities for collaboration between BHI and clinical
pharmacy.
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• There may be missing patients due to inconsistent reporting.
• All previously trialed agents may not be documented in the EMR.
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Figure 3: Reason for Drug Discontinuation
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